Registry, Department of Breast Medical Oncology, and Department of Laboratory Medicine were cross-referenced for patients with breast cancer, who were also identified as having HCV. Eligible patients had a diagnosis of invasive breast cancer, breast cancer treatment at MDACC, and a diagnosis of HCV.
introduction
According to the Centers for Disease Control and Prevention, approximately 3.2 million Americans are currently affected with chronic hepatitis C infection [1] . Hepatitis C (HCV) is the most common blood-borne infection in the United States, with an estimated 19 000 new cases yearly. Median time from infection to cirrhosis is 30 years [2] . Factors that have been associated with the rate of progression include duration of infection, age, gender, alcohol intake, HIV coinfection, and low CD4 count. While effective treatment exists, the indolent nature of this virus has led to increasing death rates due to inadequate detection and treatment [3] .
In comparison, breast cancer is the most commonly diagnosed malignancy among women in the United States. In 2008, an estimated 184 450 new cases of breast cancer will be diagnosed, with an estimated 41 000 deaths [4] . While previous research has yielded important findings on the reactivation and management of hepatitis B during the treatment of breast cancer, little information exists about the treatment of breast cancer in the setting of chronic HCV [5] [6] [7] .
We have updated and expanded the data previously reported on our cohort of breast cancer patients with HCV who were treated at the University of Texas M.D. Anderson Cancer Center (MDACC) between 2000 and 2006 [8, 9] . In this article we describe a more detailed follow-up of 45 HCV patients, aged 18 years or older, with newly diagnosed invasive breast cancer, who were treated at MDACC between 1 January 2000 and 7 July 2008.
methods
Following approval for data collection and analysis by the MDACC Institutional Review Board, the databases of the MDACC Tumor Registry, the Department of Breast Medical Oncology, and the Department of Laboratory Medicine were cross-referenced for patients with breast cancer, who were also identified as having hepatitis C. As a result of this endeavor, 90 patients were identified. The electronic medical records of these patients were then reviewed for eligibility. To be eligible for this retrospective study, patients were required to have a diagnosis of invasive breast cancer, documented breast cancer treatment at MDACC, and a diagnosis of HCV that could be documented by history and/or serology. Forty-five patients met these criteria. 
treatment course
Of the 45 patients meeting the criteria for this retrospective review, 36 patients received chemotherapy for their breast cancer ( Table 2) . Of the nine patients who received no chemotherapy, seven (78%) received endocrine therapy alone, while the remaining two (22%) received no systemic therapy at all. The staging distribution for those who did not receive chemotherapy was as follows: stage I (six patients), stage II (one patient), and unspecified stage (two patients).
Among the 36 patients who received chemotherapy, 18 (50%) received an anthracycline and a taxane, 13 (36.1%) received an anthracycline-based regimen only, 2 (5.6%) received taxane-based therapy only, and 3 (8.3%) received another chemotherapy regimen. Of the 36 patients, 4 (11%) patients received trastuzumab-based therapy. During chemotherapy, nine (25%) patients experienced elevations in aminotransferases. Within the group that demonstrated transaminitis, four patients received combined anthracyclineand taxane-based chemotherapy, three patients received anthracycline-based therapy alone, and two patients received taxane-based treatment alone. Sixteen (44%) patients required dose reductions or had dose delays in chemotherapy. Within this group of patients, the reasons for the changes in dosing or schedule were as follows: grade 2 or greater neutropenia (seven patients), grade 2 or greater neuropathy (three patients), grade 3 myalgias (one patient), grade 3 mucositis (one patient), prophylactic decrease in dose due to knowledge of active hepatitis C (two patients), elevation in liver function tests (one patient), and grade 2 anemia (one patient). In total, of the 36 patients who received chemotherapy, 33 (92%) patients were able to complete the number of cycles specified in the initial chemotherapy plan.
Twenty-three (63.9%) of the 36 patients who received chemotherapy demonstrated a grade 2 or greater complication based upon the National Cancer Institute Common Terminology Criteria for Adverse Events [10] . The most common complications were neutropenic fever or infection (eight patients), nonneutropenic infection (four patients), and neuropathy (eight patients). Less common grade 2 or greater complications included stomatitis (three patients), dermatitis (two patients), myalgias (two patients), severe nausea and vomiting (two patients), dehydration (two patients), pulmonary embolus (one patient), acute renal failure (one patient), diarrhea (one patient), and pancytopenia (two patients). There were no treatment-related deaths. While nine (25%) of the patients who received chemotherapy developed elevated liver enzymes, no patient developed decompensated liver disease. Among the nine patients who experienced transaminitis, four (44.1%) patients experienced an elevation of AST or ALT of 1.5 to 2 times the upper limit of the normal range (ULN), four patients demonstrated an increase in AST/ALT of greater than 2 times the ULN, and one patient's transaminitis was not quantified. After completion of chemotherapy, only 33.3% of the patients showed a decline in transaminases to baseline; the remainder continued to demonstrate elevated transaminases (see Table 3 ). Fourteen (39%) patients received growth factor support, including 10 patients who received granulocyte colony-stimulating factors only, 2 patients who received erythropoietin-stimulating agents only, and 2 patients who received both types of growth factors. At last follow-up, 69% of patients had no evidence of breast cancer.
hepatitis C treatment
As seen in Table 1 , most patients (80%) had received no treatment for their hepatitis before their breast cancer diagnosis. Among the eight patients who had received treatment for hepatitis C before their breast cancer diagnosis, five patients received pegylated interferon and ribavirin, two patients received interferon alone, and one patient received interferon and ribavirin. None of the patients received concurrent chemotherapy and therapy for hepatitis C.
discussion
This analysis represents the largest study describing the treatment of breast cancer patients who also have chronic hepatitis C. While the sample size and retrospective nature of this study lends itself to being primarily a descriptive study, a number of observations may be made. First, as the majority of these breast cancer patients (93%) were able to complete the initial chemotherapy treatment plan, this study indicates that breast cancer patients with hepatitis C can be treated with cytotoxic therapy. It is important, however, to seek the assistance of a gastroenterologist in evaluating any breast cancer patient with a history of hepatitis C before the initiation of chemotherapy to estimate the risk to benefit ratio of chemotherapy for breast cancer in this particular patient population. Among the patients who received chemotherapy, 39% of patients received growth factor support and 44% of patients required dose reductions or had dose delays during chemotherapy. In almost all cases, dose reductions/delays were necessitated by complications of therapy, rather than due to elevations of transaminases. However, it is possible that elevations in baseline transaminases could have contributed to the side-effects observed, as liver function is a determinant of the metabolism of several of the chemotherapeutic agents utilized.
In this study, most breast cancer patients had normal transaminases at baseline, indicating the importance of close monitoring of liver function tests during the treatment course, as 25% of these patients eventually developed an increase in ALT and/or AST during chemotherapy. The percentage of patients who experienced transaminitis during chemotherapy may have been higher than the observed value of 25%, as another 25% of patients did not undergo ALT or AST monitoring during chemotherapy. We noted that, among the Persistent LFT abnormalities 4
Persistent LFT abnormalities were defined as abnormalities that were present ‡1 month after the completion of chemotherapy.
patients who experienced increases in their transaminases, four patients received combined anthracycline-and taxane-based chemotherapy, three patients received anthracycline-based therapy alone, and two patients received taxane-based treatment alone. Thus, there did not appear to be a clear relationship between the type of cytotoxic therapy and an increase in transaminases. However, it is unclear whether the type of chemotherapy chosen was influenced by baseline abnormalities in AST and/or ALT or concerns about underlying liver dysfunction. Although there were no treatment-related deaths and no patient developed decompensated liver disease while receiving chemotherapy, there was a high rate (63.9%) of side-effects that were grade 2 or higher among our cohort of breast cancer patients with chronic hepatitis C. A related retrospective study, conducted at MDACC in 1986, reported the incidence of subclinical hepatic toxicity in 190 patients who were receiving FAC [5-fluorouracil (5-FU), doxorubicin, and cyclophosphamide] for the treatment of breast cancer in the adjuvant and metastatic settings [11] . The study demonstrated that 35% of patients with normal baseline liver function tests developed an increase in AST while receiving FAC in the adjuvant setting. These numbers compare closely with our own study. Similarly, a study carried out 30 years ago that involved 24 women who received CMF (cyclophosphamide, methotrexate, and 5-FU) in the adjuvant setting also reported a high incidence of hepatic toxicity [12] . In this study, the authors found that of the 21 women who had normal serum AST levels at baseline, 17 patients developed alterations in AST during chemotherapy. Unfortunately, both these previous studies did not provide details on other chemotherapy-related toxic effects, preventing a comparison of other adverse effects between patients with and without hepatitis C. Given the similarity in rates of hepatic toxicity in the presence (or absence) of hepatitis C, these studies indicate that the incidence of transaminitis may not be significantly affected by the presence of hepatitis C.
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